Oncology
Switching from FOLFIRI plus cetuximab to FOLFIRI plus bevacizumab leads to acceptable survival outcomes and a reduction in severe dermatological toxicities in patients with RAS wild-type (RASwt) metastatic colorectal cancer (mCRC), according to the results of a single-arm phase II HYBRID trial.
Post hoc analysis of the phase III PAOLA-1/ENGOT-ov25 trial reports respective 5-year progression-free survival (PFS) rates of 72 percent vs 28 percent and 5-year overall survival (OS) rates of 88 percent vs 61 percent for maintenance olaparib plus bevacizumab vs bevacizumab alone in lower-risk homologous recombination deficiency (HRD)–positive patients with newly diagnosed advanced ovarian cancer.
Singapore’s Health Sciences Authority recently approved axicabtagene ciloleucel (Yescarta) for the treatment of relapsed or refractory large B-cell lymphoma (LBCL) in adults after ≥2 lines of systemic therapy. Shedding light on this innovative therapy, Dr Matthew Frank, Assistant Professor of Medicine specializing in Blood and Marrow Transplantation and Cellular Therapy at Stanford University, Stanford, California, US, discussed landmark trial data, some real-world evidence, and their implications for patient selection and adverse event management during the Yescarta Commercial Launch in Singapore in May.
Biologic medicines are a category of very specific, highly effective medicines produced by a sophisticated and complex process involving living system1. Most of them are very large, complex molecules or mixtures of molecules, and many are produced using recombinant DNA technology. These medicines have revolutionised the treatment and prevention of many disabling and life-threatening diseases including cancers, Crohn’s disease, ulcerative colitis, diabetes, rheumatoid arthritis, osteoporosis, psoriasis, human immunodeficiency virus, multiple sclerosis, growth deficiencies, and more1.
Maintenance treatment with niraparib, a potent, highly selective PARP* inhibitor, provides a favourable overall survival (OS) trend compared with placebo in Chinese patients with platinum-sensitive recurrent ovarian cancer (PSROC), regardless of germline BRCA (gBRCA) mutation status, according to the final analysis of the NORA trial presented at SGO 2024.
The use of next generation sequencing (NGS) could help identify patients with ovarian cancer who would benefit from targeted therapies, according to a small retrospective study from Korea.